Late Breaking Abstract - Asthma exacerbation rate reduction with benralizumab in an integrated analysis of the real-world XALOC-1 study
D. Jackson (London, United Kingdom), G. Pelaia (Catanzaro, Italy), A. Padilla-Galo (Marbella, Málaga, Spain), M. Watt (London, United Kingdom), S. Kayaniyil (Toronto, Canada), S. Boarino (Milan, Italy), J. Tena (Spain, Spain), V. Shih (Gaithersburg, MD, United States), T. Tran (Gaithersburg, MD, United States), D. Arbetter (Boston, MA, United States), D. Cohen (Gaithersburg, MD, United States), R. Katial (Denver, CO, United States), J. Kwiatek (Gaithersburg, MD, United States), A. Shavit (Wedel, Germany), B. Emmanuel (Gaithersburg, MD, United States), P. Nair (Hamilton/Montreal, Canada)
Source: International Congress 2022 – Late-breaking abstracts in airway disease
Session: Late-breaking abstracts in airway disease
Session type: Thematic Poster
Number: 4187
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Jackson (London, United Kingdom), G. Pelaia (Catanzaro, Italy), A. Padilla-Galo (Marbella, Málaga, Spain), M. Watt (London, United Kingdom), S. Kayaniyil (Toronto, Canada), S. Boarino (Milan, Italy), J. Tena (Spain, Spain), V. Shih (Gaithersburg, MD, United States), T. Tran (Gaithersburg, MD, United States), D. Arbetter (Boston, MA, United States), D. Cohen (Gaithersburg, MD, United States), R. Katial (Denver, CO, United States), J. Kwiatek (Gaithersburg, MD, United States), A. Shavit (Wedel, Germany), B. Emmanuel (Gaithersburg, MD, United States), P. Nair (Hamilton/Montreal, Canada). Late Breaking Abstract - Asthma exacerbation rate reduction with benralizumab in an integrated analysis of the real-world XALOC-1 study. 4187
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|